Osteoporosis access landscape: Prolia's 10 denosumab biosimilars and Evenity

The medical management of postmenopausal osteoporosis and high-risk bone loss is undergoing its most rapid formulary shift in over a decade. The expiration of primary patent exclusivity for Amgen's Prolia (denosumab 60 mg) has ushered in a dense competitive landscape featuring ten FDA-licensed interchangeable 351(k) denosumab biosimilars—the largest interchangeable biosimilar field in the U.S. market. Nine are marketed as dual 60 mg (Prolia-type) / 120 mg (Xgeva-type) brand pairs, while Teva's Ponlimsi (denosumab-adet), approved March 2026, is licensed for Prolia (osteoporosis) indications only.

Simultaneously, major commercial and Medicare Advantage payers are updating medical benefit coverage criteria. Effective July 1, 2026, major national health plans including UnitedHealthcare have implemented tiered preferred-product hierarchies for denosumab, favoring select biosimilars over reference Prolia or competing biosimilars.

At the same time, prescribing for high-fracture-risk patients is increasingly shifting toward bone-forming anabolic agents—led by Evenity (romosozumab-aqqg) and generic teriparatide—before transitioning patients to antiresorptive maintenance therapy.

This comprehensive access guide provides pharmacy benefit managers (PBMs), health system specialty pharmacy directors, and endocrinology access teams with a detailed analysis of the 2026 osteoporosis therapeutic landscape, mapping biosimilar competition, payer preferred-product criteria, anabolic vs. antiresorptive clinical sequencing, rebound fracture mitigation protocols, and post-marketing adverse event surveillance data.

---

Executive Summary & Osteoporosis Formulary Matrix (2026)

                    Osteoporosis Therapeutic Tiering & Access Architecture
                    ======================================================

   Tier 1: Oral Antiresorptives        [Oral Bisphosphonates] alendronate, risedronate
            (First-Line)               -> Low cost, generic, NADAC-benchmarked

   Tier 2: Injectable Antiresorptives  [Prolia & 10 Interchangeable Biosimilars] denosumab
            (Second-Line SC q6mo)      -> Jubbonti, Stoboclo, Ospomyv, etc.
                                       -> Subject to Jul 2026 Payer Preferred Lists

   Tier 3: Anabolic / Bone-Forming     [Evenity] romosozumab (dual anabolic/antiresorptive, CV Boxed Warning)
            (High Fracture Risk)       [Generic Teriparatide] daily SC anabolic (Forteo reference)

---

The Ten Interchangeable Denosumab Biosimilars (Purple Book Benchmark)

According to official FDA Purple Book registry data, ten 351(k) interchangeable denosumab biosimilars referencing Prolia have achieved FDA licensure as of August 2026. Nine are marketed as dual-brand pairs — a 60 mg Prolia-type biosimilar for osteoporosis alongside a 120 mg Xgeva-type biosimilar for oncology bone metastases under separate brand names sharing a single BLA — while Teva's Ponlimsi (denosumab-adet, approved March 2026) is licensed for Prolia (osteoporosis) indications only and has no Xgeva-type counterpart.

                    Denosumab Dual-Brand Architecture per Manufacturer
                    =================================================

                           [Developer 351(k) BLA Licensure]
                                          |
                +-------------------------+-------------------------+
                |                                                   |
     [60 mg SC Every 6 Months]                             [120 mg SC Every 4 Weeks]
     Prolia-Type Osteoporosis Brand                       Xgeva-Type Oncology Brand
     (e.g., Sandoz JUBBONTI)                              (e.g., Sandoz WYOST)

Full FDA Purple Book Interchangeable Denosumab Roster

Note: For broader context on how interchangeable biologic designations are assigned across classes, see our analysis of interchangeable biosimilars by the numbers and Humira biosimilars compared. For drug-specific HCPCS coding details, see our Prolia and Xgeva denosumab biosimilars guide.

---

Payer Preferred-Product Dynamics: The July 2026 Shift

Unlike small-molecule generic drugs where substitution occurs automatically at retail pharmacies, specialty biologic substitution is governed by state pharmacy laws, payer medical benefit policies, and facility buy-and-bill fee schedules.

            UnitedHealthcare Denosumab Medical Policy Dynamics (Eff. 07/01/2026)
            ====================================================================

      Preferred Products (No Step-Through Required):
      --> Prolia (reference denosumab, Amgen)
      --> Stoboclo (denosumab-bmwo, Celltrion)

      Non-Preferred Products (Requires Prior Authorization & Trial of Preferred):
      --> Jubbonti (denosumab-bbdz, Sandoz)
      --> Ospomyv, Conexxence, Osvyrti, Bosaya, Enoby, Bildyos, Boncresa, Ponlimsi

Key Policy Requirements & Buy-and-Bill Economics

1. Preferred Product Mandates: Under updated commercial drug policies (such as UnitedHealthcare's July 1, 2026 policy update), coverage for non-preferred denosumab products requires documented clinical failure, intolerance, or contraindication to both reference Prolia and preferred biosimilar Stoboclo (denosumab-bmwo); any denosumab product not named as preferred is treated as non-preferred.
2. Buy-and-Bill Economics: Provider clinics utilizing buy-and-bill reimbursement under Medicare Part B (Average Sales Price + 6%) must carefully evaluate ASP updates. Biosimilars carry an ASP+6% calculation based on 6% of the reference product's ASP, creating a financial incentive for provider practices to adopt biosimilars when available at lower acquisition costs.
3. PBM Pharmacy Channel Routing: For self-administered 60 mg denosumab prescriptions filled under pharmacy benefits, PBM preferred formularies may select different preferred biosimilar NDCs than medical benefit plans, requiring specialty pharmacies to verify benefit channel routing prior to dispensing.

To examine how baseline acquisition costs compare across oral and injectable osteoporosis agents, see our analysis of CMS NADAC drug acquisition costs.

---

Where Does Evenity Fit in the Anabolic vs. Antiresorptive Sequence?

For postmenopausal women at high risk for fracture (defined as a history of osteoporotic fracture, multiple risk factors, or failure of prior antiresorptive therapy), clinical guidelines from the American Association of Clinical Endocrinologists (AACE) recommend starting treatment with an anabolic agent to rapidly build bone mineral density (BMD) before transitioning to antiresorptive maintenance.

                      Recommended Anabolic-to-Antiresorptive Sequence
                      ==============================================

   Phase 1: Bone Formation (12–24 Months)          Phase 2: Antiresorptive Consolidation
   --------------------------------------          -------------------------------------
   [Evenity] romosozumab SC monthly (12 mo max)     ---> [Denosumab / Biosimilar] SC q6mo
   or [Teriparatide / Tymlos] SC daily (24 mo max)       or [Zoledronic Acid] IV annually

Evenity (Romosozumab) Access & Safety Profile

• Mechanism: Dual-action monoclonal antibody that binds sclerostin, stimulating osteoblastic bone formation while inhibiting osteoclastic bone resorption.
• Dosing: 210 mg SC monthly (administered as two separate 105 mg subcutaneous injections by a healthcare provider) for a maximum duration of 12 monthly doses.
• Cardiovascular Boxed Warning: Evenity carries a prominent Boxed Warning regarding potential increased risk of myocardial infarction, stroke, and cardiovascular death. It should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year.
• Payer PA Requirements: Payers require documentation of T-score ≤ -2.5 with a prior fragility fracture, or T-score ≤ -3.0 without fracture, along with confirmation of baseline cardiovascular risk assessment.

Generic Teriparatide & Tymlos Tiering

• Teriparatide (Generic Forteo): Recombinant human parathyroid hormone (1-34) administered as a daily self-injection for up to 24 months. Generic entry has significantly reduced WAC pricing, making it a preferred anabolic on many Part D specialty tiers. For details on generic combination product access, review our analysis of Forteo/teriparatide generic entry.
• Tymlos (Abaloparatide): Synthetic PTHrP analogue providing comparable anabolic efficacy; often positioned as a non-preferred brand relative to generic teriparatide.

---

Comprehensive Osteoporosis Class Comparison Matrix

---

Denosumab Adverse Event Profile: Post-Marketing FAERS Baseline

Safety surveillance for denosumab is critical for specialty pharmacists monitoring long-term therapy. Analysis of post-marketing adverse event data from the FDA Adverse Event Reporting System (FAERS) for reports received between 2018 and 2026 establishes the quantitative safety profile of denosumab across all indications.

Cumulative Denosumab FAERS Benchmark (2018–2026)

Across the 2018–2026 surveillance window, the FDA database recorded 96,722 any-role adverse event reports referencing denosumab.

       Denosumab Safety Signals in FAERS Surveillance (96,722 Any-Role Reports)
       ========================================================================

       Serious Outcomes        [#################################] 49,328 (51.0%)
       Reported Deaths         [#####] 7,834 (8.1%)
       Osteonecrosis of Jaw    [###] 4,103 (4.2%)

Note: FAERS denosumab data reflects substance-level reports combining Prolia (osteoporosis, 60 mg q6mo) and Xgeva (oncology, 120 mg q4mo). These counts represent any drug mention in a report (a report may list several drugs) and quantify the post-marketing surveillance signal rather than attributable incidence; adverse event shares such as ONJ are heavily driven by the higher cumulative exposure in Xgeva oncology patients and should not be attributed solely to postmenopausal osteoporosis care.

For comparison with oral antiresorptive safety, see our study on bisphosphonate adverse events by the numbers.

---

Managing Denosumab Rebound Vertebral Fractures & Transition Protocols

Unlike bisphosphonates, which remain bound to bone matrix for years after treatment discontinuation, denosumab's RANKL inhibition is fully reversible upon drug clearance.

                  Denosumab Discontinuation & Rebound Physiology
                  ==============================================

   Active Denosumab Therapy (q6mo) ---> Discontinuation (>7 Months Post-Dose)
   ------------------------------       -----------------------------------
   [Suppressed Osteoclasts]             --> Rapid Osteoclast Over-Activation
   [Maintained BMD]                     --> High Bone Turnover & Bone Loss
                                        --> Multiple Rebound Vertebral Fractures

Clinical Mitigation & Transition Protocol

1. Strict 6-Month Scheduling: Specialty pharmacies and infusion centers must enforce automated reminder systems to ensure patients receive 60 mg denosumab injections within 6 months (+/- 2 weeks) of the prior dose.
2. Mandatory Consolidation Therapy: If denosumab therapy must be discontinued (due to adverse events, patient preference, or coverage loss), clinicians must initiate a potent bisphosphonate (e.g., IV zoledronic acid 5 mg administered 6 months after the final denosumab dose, or oral alendronate daily) to lock in BMD gains and prevent rebound fractures.
3. Payer Interruption Management: If a payer prior authorization dispute delays a denosumab refill past 6 months, specialty access teams must immediately submit an urgent appeal citing the established clinical risk of rebound multiple vertebral fractures upon treatment gap.

---

Specialty Pharmacy Prior Authorization Appeals & Step-Therapy Exemption Framework

Navigating PBM step-therapy mandates and preferred biosimilar lists requires structured documentation from health system specialty access teams.

                 Prior Authorization & Appeals Decision Workflow
                 ===============================================

   [Prescription Received] ---> [Payer Preferred List Check]
                                        |
     +----------------------------------+----------------------------------+
     |                                                                     |
   [Preferred Product (Prolia / Stoboclo)]               [Non-Preferred Product (Jubbonti, etc.)]
   -> Direct Approval / Express PA                       -> Submit Step-Therapy Exemption Request:
                                                            1. Documented preferred trial or intolerance
                                                            2. Clinical rationale for specific NDC

Key Documentation Checklist for Prior Authorization Approval

• Baseline DEXA Scan Results: T-score ≤ -2.5 at lumbar spine, femoral neck, or total hip, or presence of fragility fracture regardless of T-score.
• Trial & Failure of Oral Bisphosphonates: Documented trial (at least 12 months) of alendronate or risedronate, or documented GI contraindication (e.g., esophageal stricture, Barrett's esophagus, severe GERD).
• Cardiovascular Risk Screening for Evenity: Statement confirming no myocardial infarction or stroke within the preceding 12 months for Evenity prior authorization requests.
• Continuous Denosumab Compliance Record: For renewal authorization, provide historical administration logs to demonstrate no treatment gap exceeding 7 months.

---

Clinical & Administrative Summary for 2026 Formulary Management

1. Verify State Biosimilar Substitution Laws: Confirm whether local pharmacy regulation allows automatic substitution of FDA-designated interchangeable denosumab biosimilars at retail/specialty pharmacies or requires provider notification.
2. Review Medical Benefit Policy Tiering: Check plan-specific medical policies (such as UnitedHealthcare's July 2026 update) before selecting buy-and-bill denosumab products to avoid claim denials for non-preferred NDCs.
3. Enforce Anabolic Sequence Protocols: Ensure that high-risk fracture patients complete their 12-month (Evenity) or 24-month (teriparatide) anabolic course before transitioning to denosumab or bisphosphonate consolidation.
4. Prevent Denosumab Rebound Fractures: Maintain strict compliance tracking to ensure patients do not experience treatment gaps beyond 6 months, as abrupt discontinuation of denosumab leads to rapid loss of BMD and heightened risk of multiple vertebral fractures.

---

Frequently Asked Questions (FAQ)

Are all nine denosumab biosimilars interchangeable with Prolia?

Yes. All ten FDA-licensed 351(k) denosumab biosimilars (the nine dual-brand pairs plus Teva's Prolia-only Ponlimsi) hold FDA interchangeable designations in the Purple Book, allowing substitution subject to state pharmacy laws and payer preferred-product policies.

Why do denosumab biosimilar developers launch under two different brand names?

Each developer assigns one brand name to the 60 mg Prolia-type product (for osteoporosis) and a separate brand name to the 120 mg Xgeva-type product (for oncology bone metastases), allowing separate NDCs and benefit channel routing while sharing a single underlying BLA.

Does Evenity require prior authorization?

Yes. Commercial and Medicare Advantage payers require prior authorization for Evenity, verifying high fracture risk (history of osteoporotic fracture or low T-score) and confirming that the patient has no history of myocardial infarction or stroke within the preceding 12 months.

---

Sources

1. U.S. Food and Drug Administration: FDA Purple Book: Database of Licensed Biological Products. License listings for reference denosumab (BLA 125320) and 351(k) biosimilars. https://purplebooksearch.fda.gov/
2. UnitedHealthcare: Denosumab (Prolia & Xgeva) Commercial Medical Benefit Drug Policy. Effective July 1, 2026. https://www.uhcprovider.com/content/dam/provider/docs/public/policies/comm-medical-drug/denosumab-prolia-xgeva.pdf
3. Sandoz: Sandoz Launches First and Only Interchangeable Denosumab Biosimilars in the US. Corporate Press Release, June 2025. https://www.sandoz.com/sandoz-launches-first-and-only-interchangeable-denosumab-biosimilars-us-providing-new-affordable
4. The ASCO Post: FDA Approves First Interchangeable Biosimilars to Wyost and Jubbonti for Bone Conditions. Regulatory Review. https://ascopost.com/news/march-2024/fda-approves-denosumab-biosimilars
5. U.S. Food and Drug Administration: FDA Adverse Event Reporting System (FAERS) Public Data Set. Post-Marketing Safety Reports for Denosumab (2018–2026 Surveillance Cohort). https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers